From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.

Table 1. Binding affinities of synthetic peptides

HLA	Position	Length, mer	Sequence	Score	Fluorescence index
A*0201	Aur-$A_{271-279}$	9	KIADFGWSV	3911	0.93
A*0201	Aur-A_{63-71}	9	KLVSSHKPV	243	0.23
A*0201	Aur-$A_{207-215}$	9	YLILEYAPL	147	1.47
A*0201	$WT1_{7-15}$	9	DLNALLPAV	12	0.06
A*0201	$CMVpp65_{495-503}$	9	NLVPMVATV	160	1.71
A*2402	Aur-$A_{207-215}$	9	YLILEYAPL	6	0.99
A*2402	$WT1_{7-15}$	9	DLNALLPAV	0.18	0.02
A*2402	$WT1_{235-243}$Y	9	CYTWNQMNL	200	4.5

The binding affinities of synthetic peptides for HLA molecules were predicted by computer algorithms available on the National Institutes of Health BIMAS website (http://www-bimas.cit.nih.gov/molbio/hla_bind). The binding affinities of synthetic peptides for HLA molecules were evaluated by MHC stabilization assay as detailed in "HLA peptide–binding assay."

of the peptides used in this study are listed in Table 1. All the peptides were synthesized with a purity exceeding 80%.

HLA peptide–binding assay

Binding affinity of peptides for the HLA-A*0201 or HLA-A*2402 molecule was assessed by an HLA-A*0201 or HLA-A*2402 stabilization assay as described previously.[28,29] Briefly, the HLA-A*0201–positive cell line (T2) or the *HLA-A*2402* gene–transfected T2 cell line (T2-A24) was plated in 24-well plates at 10^6 cells per well and incubated overnight with the candidate peptides at a concentration of 10 μM in serum-free RPMI 1640 medium. The T2 and T2-A24 cells were washed twice with phosphate-buffered saline (PBS), and then incubated with fluorescein isothiocyanate (FITC)–conjugated anti–HLA-A2 or HLA-A24 monoclonal antibody (MoAb; One Lambda, Canoga Park, CA) at 4°C for 20 minutes. The cells were washed and suspended in 1 mL PBS and analyzed using a flow cytometer (FACSCalibur; Becton Dickinson, San Jose, CA). Measurement of mean fluorescence intensity and analysis of data were done with CellQuest Software (Becton Dickinson). The fluorescence index (FI) was calculated as FI = (sample mean − background mean) / background mean.

Cell lines, freshly isolated leukemia cells, and normal cells

Approval for this study was obtained from the institutional review board of Ehime University Hospital. Written informed consent was obtained from all patients, healthy volunteers, and parents of cord blood donors in accordance with the Declaration of Helsinki.

B-lymphoblastoid cell lines (B-LCLs) were established by transformation of peripheral blood B lymphocytes with Epstein-Barr virus. LCLs, T2, T2-A24, and leukemia cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS). The *HLA-A*0201* gene–transfected C1R cell line (C1R-A*0201; kindly provided by Dr A. John Barrett, National Heart, Lung, and Blood Institute [NHLBI], Bethesda, MD) was cultured in RPMI 1640 medium supplemented with 10% FCS and 2 mM L-glutamine. Peripheral blood mononuclear cells (PBMCs) and bone marrow mononuclear cells (BMMCs) from leukemia patients and healthy volunteers, and cord blood mononuclear cells (CBMCs) from healthy donors were isolated and stored in liquid nitrogen until use. All leukemia samples contained more than 95% leukemia cells. $CD34^+$ cells from BMMCs and CBMCs were isolated using $CD34^+$ cell-isolating immunomagnetic beads (MACS beads; Miltenyi Biotec, Auburn, CA). In some experiments, BMMCs and CBMCs were stained with FITC-conjugated anti-CD34 MoAb and phycoerythrin (PE)–conjugated anti-CD38 MoAb, and $CD34^+CD38^{high}$ cells and $CD34^+CD38^{low}$ cells were sorted with an EPICS ALTRA cell sorter (Beckman-Coulter, Fullerton, CA).

Generation of Aur-A peptide–specific CTL lines

Aur-A peptide–specific CTLs were generated as described previously.[30] Briefly, monocytes ($CD14^+$ mononuclear cells) were isolated from PBMCs of HLA-A*0201–positive individuals using $CD14^+$ cell-isolating MACS beads. Monocytes were cultured in RPMI 1640 medium supplemented with 10% FCS, 75 ng/mL recombinant human granulocyte-macrophage colony-stimulating factor, 10 ng/mL recombinant human interleukin 4 (IL-4; R&D Systems, Minneapolis, MN), and 100 U/mL recombinant human tumor necrosis factor-α (Dainippon Pharmaceutical, Osaka, Japan) to generate mature dendritic cells (DCs). $CD8^+$ T lymphocytes isolated from PBMCs using $CD8^+$ cell-isolating MACS beads were plated in 96-well round-bottomed plates at 10^5 cells per well and stimulated with 10^4 autologous DCs pulsed with synthetic peptide derived from Aur-A at a concentration of 10 μM. The cells were cultured in RPMI 1640 medium supplemented with 10% human AB serum. After 7 days, the cells were restimulated with 10^4 autologous DCs pulsed with Aur-A peptide, and 10 U/mL IL-2 (Boehringer Mannheim, Mannheim, Germany) was added 4 days later. After culturing for a further 3 days (day 15 of culture), the cells were stimulated with 10^5 autologous PBMCs treated with mitomycin C (MMC; Kyowa Hakko, Tokyo, Japan) pulsed with Aur-A peptide. Thereafter, the cells were restimulated weekly by MMC-treated autologous PBMCs pulsed with Aur-A peptide. The Aur-A peptide–specific cytotoxic activity of growing cells was examined by standard ^{51}Cr-release assay.

Cytotoxicity assays

The standard ^{51}Cr-release assays were performed as described previously.[31] Briefly, 10^4 ^{51}Cr-labeled ($Na_2{}^{51}CrO_4$; New England Nuclear, Boston, MA) target cells and various numbers of effector cells in 200 μL RPMI 1640 medium supplemented with 10% FCS were seeded into 96-well round-bottom plates. The target cells were incubated with or without synthetic peptide for 2 hours before adding the effector cells. To assess the HLA class I restriction of cytotoxicity, target cells were incubated with an anti–HLA class I framework MoAb (w6/32; ATCC, Manassas, VA) or an anti–HLA-DR MoAb (L243; ATCC) at an optimal concentration (10 μg/mL) for 1 hour before adding the effector cells. Aur-A peptide specificity of cytotoxicity was examined by cold target inhibition assay as follows. ^{51}Cr-labeled target cells (hot targets) were mixed with various numbers of ^{51}Cr-unlabeled Aur-A peptide–loaded HLA-A*0201–positive LCLs or with ^{51}Cr-unlabeled Aur-A peptide–loaded HLA-A*0201–negative LCLs (cold targets). After incubation with the effector cells for 5 hours, 100 μL supernatant was collected from each well. The percentage of specific lysis was calculated as: (experimental release cpm − spontaneous release cpm) / (maximal release cpm − spontaneous release cpm) × 100 (%).

Quantitative analysis of *Aur-A* mRNA expression

Total RNA was extracted from each sample with an RNeasy Mini Kit (QIAGEN, Hilden, Germany) in accordance with the manufacturer's instructions. Quantitative real-time polymerase chain reaction (QRT-PCR) of *Aur-A* mRNA (Hs00269212_m1) and *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*) mRNA (4326317E) as an internal control was performed using the TaqMan Gene Expression assay (Applied Biosystems, Foster City, CA) in accordance with the manufacturer's instructions using an ABI Prism 7700 Sequence Detection System (Applied Biosystems). The expression level of *Aur-A* mRNA was corrected by reference to that of *GAPDH* mRNA, and the relative amount of *Aur-A* mRNA in each sample was calculated by the comparative ΔCt method.

From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.

Western blotting of Aur-A protein

Western blotting was performed as follows. Briefly, 10^6 cells were lysed in lysis buffer (25 mM HEPES, pH 7.5, 1% NP-40, 50 mM NaCl, 5 mM EDTA) with a protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland), and then incubated on ice, sonicated, frozen, and thawed. After centrifugation at 12 000*g* for 15 minutes at 4°C, the supernatant was collected as the lysate. After addition of sodium dodecyl sulfate (SDS) buffer, the total cell lysates were subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE), and blotted onto nitrocellulose membranes. The blots were reacted with anti–Aur-A mouse MoAb (Abcam, Cambridge, United Kingdom) followed by incubation with horseradish peroxidase-conjugated anti-mouse IgG antibody (GE Healthcare, Little Chalfont, United Kingdom). The probed proteins were visualized using an enhanced chemiluminescence system (GE Healthcare). The blotted membranes were also examined with anti–β-actin mouse MoAb (Sigma-Aldrich, St Louis, MO) to confirm that samples of equal volume had been loaded.

Detection of Aur-$A_{207-215}$–specific CTL precursors in leukemia patients and healthy individuals by tetramer assays and enzyme-linked immunospot assays

HLA-A*0201/Aur-$A_{207-215}$ peptide and HLA-A*2402/Aur-$A_{207-215}$ peptide tetramers were produced as described previously.[32,33] Briefly, recombinant HLA-A*0201 or HLA-A*2402 and the β_2-microglobulin molecule were generated by the gene-transfer method. Expression of the HLA heavy chain was limited to the extracellular domain, and the C terminus of the domain was modified by addition of a substrate sequence for the biotinylating enzyme BirA. Monomeric HLA-peptide complexes were folded in vitro by adding the HLA protein to β_2-microglobulin in the presence of Aur-$A_{207-215}$ (YLILEYAPL), HIV-1 p17 Gag_{77-85} (SLYNTVATL), or HIV-1 $Env_{584-592}$ (RYLRDQQLL) peptide. After gel purification, the HLA complex was biotinylated using recombinant BirA enzyme (Avidity, Denver, CO), and HLA-peptide tetramers were made by mixing the biotinylated HLA with PE-labeled streptavidin (Molecular Probes, Eugene, OR) at a molar ratio of 4:1.

PBMCs from HLA-A*0201– or HLA-A*2402–positive leukemia patients and healthy individuals were seeded in 24-well plates at 1.5×10^6 per well in the presence of the Aur-$A_{207-215}$ peptide at a concentration of 10 μM in RPMI 1640 medium supplemented with 10% human AB serum and 10 U/mL IL-2. After culturing for 14 days, Aur-$A_{207-215}$–specific CTL frequencies in cultured cells were examined by tetramer staining. Cultured PBMCs were stained with FITC-conjugated anti-CD8 MoAb and the tetramer at a concentration of 20 μg/mL at 4°C for 20 minutes. After washing twice, stained cells were analyzed using a FACSCalibur and Cell Quest Software.

Enzyme-linked immunospot (ELISPOT) assays were carried out as described previously.[33] Briefly, 96-well flat-bottom MultiScreen-HA plates with a nitrocellulose base (Millipore, Bedford, MA) were coated with 10 μg/mL anti–interferon-γ (IFN-γ) MoAb (R&D Systems) and incubated overnight at 4°C. After being washed with PBS, the plates were blocked with the assay medium for 1 hour at 37°C. T2-A24 cells (5.0×10^4/well) were pulsed with Aur-$A_{207-215}$ peptide at a concentration of 10 μM or with PBS alone, and incubated in RPMI 1640 medium supplemented with 10% FCS for 1 hour at 37°C. Then, the responder cells generated were seeded into each well to mix with the target peptide–loaded T2-A24 cells, and the plates were incubated in a 5% CO_2 incubator at 37°C for 20 hours. After incubation, plates were washed vigorously with PBS containing 0.1% Tween 20. A polyclonal rabbit anti–IFN-γ antibody (Endgen, Woburn, MA) was added to each well and the plates was left for 90 minutes at room temperature, followed by exposure to peroxidase-conjugated goat anti-rabbit IgG (Zymed, San Francisco, CA) for an additional 90 minutes. To reveal IFN-γ–specific spots, 100 μL 0.1 M sodium acetate buffer (pH 5.0) containing 3-amino-9-ethylcarbazole (Sigma-Aldrich) and 0.015% H_2O_2 were added to each well. After 40 minutes, the color reaction was interrupted by washing with water, and the plates were dried. Diffuse large spots were counted under a dissecting microscope (Figure S1A, available on the *Blood* website; see the Supplemental Materials link at the top of the online article).

Results

Binding activities of Aur-A peptides for HLA-A*0201 and HLA-A*2402 molecules

The BIMAS-predicted binding scores and results of the binding assay for the HLA-A*0201 and HLA-A*2402 molecules with the 3 candidate Aur-A peptides and the positive and negative control peptides are summarized in Table 1. Among the 3 candidate Aur-A peptides, Aur-$A_{207-215}$ showed high binding affinity for HLA-A*0201 in comparison with the others. Interestingly, Aur-$A_{207-215}$ peptide appeared to be capable of binding to HLA-A*2402 as well as HLA-A*0201. These data suggest that Aur-$A_{207-215}$ peptide can elicit Aur-A–specific CTLs.

Establishment of an Aur-$A_{207-215}$ peptide–specific CTL line

By repeated stimulation of $CD8^+$ T lymphocytes with Aur-A peptide–loaded autologous DCs, as detailed in "Methods," an Aur-$A_{207-215}$ peptide–specific CTL line, designated AUR-1, was established from an HLA-A*0201–positive individual. It was possible to generate Aur-$A_{207-215}$ peptide–specific CTLs from 2 other HLA-A*0201–positive individuals; however, long-term maintenance of these CTL lines was unsuccessful. Therefore, detailed studies of the functional characteristics of Aur-A–specific CTLs were performed using AUR-1. Establishment of Aur-A_{63-71}–specific or Aur-$A_{271-279}$–specific stable CTL lines was unsuccessful. As shown in Figure 1, AUR-1 showed strong cytotoxicity against Aur-$A_{207-215}$ peptide–loaded autologous and allogeneic HLA-A*0201–positive LCLs but not Aur-$A_{207-215}$ peptide–unloaded HLA-A*0201–positive LCLs. AUR-1 did not show any cytotoxicity against Aur-$A_{207-215}$ peptide–loaded HLA-A*0201–negative allogeneic LCLs. Autologous LCLs loaded with other HLA-A*0201–binding peptides were not lysed by AUR-1 (data not shown). To confirm HLA-A*0201 restriction of Aur-$A_{207-215}$ peptide–specific cytotoxicity mediated by AUR-1, cytotoxic activity against the *HLA-A*0201* gene–transfectant cell line C1R-A*0201 was examined. AUR-1 was cytotoxic to C1R-A*0201 cells only in the presence of Aur-$A_{207-215}$ peptide, and this cytotoxicity was significantly attenuated by anti–HLA class I MoAb but not by anti–HLA-DR MoAb (data not shown). These data indicate that Aur-$A_{207-215}$–specific cytotoxicity of AUR-1 is restricted by HLA-A*0201.

Aur-$A_{207-215}$–specific and HLA-A*0201–restricted lysis of Aur-A–expressing leukemia cell lines by AUR-1

Aur-A mRNA expression levels in leukemia cell lines and PBMCs of healthy people as a control were assessed by the QRT-PCR method. The amount of *Aur-A* mRNA in each cell line relative to that in the chronic myelogenous leukemia (CML) cell line K562 was calculated. Similarly, Aur-A protein expression levels in leukemia cell lines and normal PBMCs were examined by Western blotting. As shown in Figure 2A, Aur-A appeared to be expressed abundantly in all the leukemia cell lines examined, including acute myelogenous leukemia (AML) and CML cell lines. In contrast, expression of Aur-A in normal PBMCs was undetectable.

AUR-1 exerted cytotoxicity against the HLA-A*0201–positive leukemia cell lines GANMO-1 and CMK11-5, but not against the HLA-A*0201–negative cell lines MEG01, KAZZ, OUN-1, and K562 (Figure 2B). As shown in Figure 2C, cytotoxicity against leukemia cell lines mediated by AUR-1 was inhibited by addition of anti–HLA class I framework MoAb but not anti–HLA-DR MoAb. The cold target inhibition assay showed that the cytotoxicity of AUR-1 against the HLA-A*0201–positive leukemia cell line was significantly abrogated

From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.



Figure 1. Establishment of an HLA-A*0201–restricted and Aur-$A_{207-215}$ peptide–specific CTL line, AUR-1. The cytotoxicity of the CTL line designated AUR-1 against various LCLs and *HLA-A*0201* gene–transfected cells (C1R-A*0201), which were loaded or unloaded with Aur-$A_{207-215}$ peptide, was determined by 4-hour ^{51}Cr-release assays at effector-to-target (E:T) ratios of 10:1, 5:1, and 2.5:1.

by adding ^{51}Cr-unlabeled Aur-$A_{207-215}$ peptide–loaded autologous LCL, but not HLA-A*0201–negative allogeneic LCL, indicating that the cytotoxicity of AUR-1 against leukemia cells is Aur-A specific (Figure 2D). These results show that AUR-1 can exert cytotoxicity against leukemia cell lines in an HLA-A*0201–restricted manner through recognition of the Aur-$A_{207-215}$ epitope that is naturally processed from Aur-A protein in leukemia cells and presented on the cell surface in the context of HLA class I molecules.

Freshly isolated leukemia cells, but not normal PBMCs or normal mitotic cells, express Aur-A abundantly and are lysed by AUR-1

Next, we examined whether Aur-A–specific CTLs can discriminate freshly isolated leukemia cells from normal cells and whether AUR-1 can lyse freshly isolated leukemia cells as well as leukemia cell lines. As shown in Figure 3A, Aur-A appeared to be overexpressed in a wide spectrum of leukemia, including acute lymphoblastic leukemia (ALL), AML, and CML, as reported previously.[17-19] Among the various kinds of leukemia, CML cells express a very high level of *Aur-A* mRNA. In contrast, expression levels of *Aur-A* mRNA in normal PBMCs and phytohemagglutinin (PHA)–stimulated peripheral blood T lymphocytes (normal mitotic cells) were extremely low in comparison with those in freshly isolated leukemia cells.

The cytotoxicity of AUR-1 against freshly isolated leukemia cells was examined by standard ^{51}Cr-release assay. Because the frequency of HLA-A*0201 in the Japanese population is less than 10%, only 3 HLA-A*0201–positive leukemia samples were available. As expected, all HLA-A*0201–positive freshly isolated leukemia cells were lysed by AUR-1; however, HLA-A*0201–negative freshly isolated leukemia cells, HLA-A*0201–positive normal PBMCs, and HLA-A*0201–positive PHA lymphoblasts were resistant to AUR-1–mediated cytotoxicity (Figure 3B). Taken together, Aur-A–specific CTLs appeared to be capable of discriminating leukemia cells from normal cells in an HLA-restricted manner.

$CD34^+$ leukemia progenitor cells, but not $CD34^+$ normal hematopoietic progenitor cells, express Aur-A abundantly and are susceptible to AUR-1–mediated cytotoxicity

Because it is important to determine whether Aur-A–specific CTLs can specifically recognize and lyse leukemia progenitors, we further examined Aur-A expression and susceptibility to AUR-1–mediated cytotoxicity of $CD34^+$ fractions in leukemia cells and normal hematopoietic cells. The $CD34^+$ cells were sorted from BMMCs of patients with CML and CBMCs, and their *Aur-A* mRNA expression was examined by QRT-PCR. As shown in Figure 4A, the expression levels of *Aur-A* mRNA in CML $CD34^+$ progenitor cells appeared to be significantly higher than in normal $CD34^+$ hematopoietic progenitor cells. Because it is suggested that leukemia stem cells and normal hematopoietic stem cells are present in the $CD34^+CD38^{low}$ fraction, we further examined Aur-A expression in $CD34^+CD38^{low}$ cells of CML BMMCs and CBMCs. Consequently, it appeared that *Aur-A* mRNA was abundantly expressed in the $CD34^+CD38^{low}$ fraction of CML (Figure 4B); however, the expression level of *Aur-A* mRNA in the $CD34^+CD38^{low}$ fraction of normal hematopoietic progenitors was significantly low (Figure 4C).

Since a sufficient number of $CD34^+CD38^{low}$ cells could not be obtained, whole $CD34^+$ cells were used as target cells for cytotoxicity assays (Figure 4D). As expected, AUR-1 exerted strong cytotoxicity against $CD34^+$ cells isolated from CML BMMCs of 2 patients. In contrast, AUR-1 did not show any cytotoxicity against normal $CD34^+$ hematopoietic progenitor cells. These data strongly suggest that Aur-A–specific CTLs can discriminate leukemia progenitor cells from normal hematopoietic stem cells and selectively inhibit the growth of leukemia stem cells, and that immunotherapy targeting Aur-A is effective and safe.

Presence of Aur-$A_{207-215}$–specific CTL precursors in peripheral blood of leukemia patients

When considering the feasibility of cellular immunotherapy for leukemia targeting Aur-A, it seems important to clarify whether Aur-A–specific CTL precursors are present in patients with leukemia. Aur-$A_{207-215}$–specific CTL precursors in HLA-A*0201–positive patients with leukemia including AML in complete remission (CR) after allogeneic hematopoietic stem cell transplantation, ALL in CR after chemotherapy, and CML in the chronic phase before imatinib therapy, and 8 healthy subjects were analyzed by tetramer assay. Because Aur-$A_{207-215}$ peptide can bind to HLA-A*2402 as well as HLA-A*0201, we also examined Aur-$A_{207-215}$–specific CTL precursors in 2 HLA-A*2402–positive

From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.



Figure 2. Expression of Aur-A in leukemia cell lines and the cytotoxicity of AUR-1 against leukemia cell lines. (A) Expression of *Aur-A* mRNA and protein in leukemia cell lines and normal PBMCs. Expression levels of *Aur-A* mRNA in the cells were determined by QRT-PCR as detailed in "Methods." The level of *Aur-A* mRNA expression in the K562 leukemia cell line, which strongly expresses Aur-A, is shown as 1.0 and the expression levels in the cells were calculated relative to this value. Aur-A protein expression was examined by Western blotting using anti–Aur-A antibody and anti–β-actin antibody as the control. (B) Cytotoxicity of the Aur-$A_{207-215}$–specific CTL line AUR-1 against leukemia cell lines. The cytotoxicity of AUR-1 to HLA-A*0201–positive and HLA-A*0201–negative leukemia cell lines was determined by 4-hour ^{51}Cr-release assays at E/T ratios of 10:1, 5:1, and 2.5:1. (C) HLA class I restriction of cytotoxicity mediated by AUR-1 against leukemia cells. The cytotoxicity of AUR-1 against leukemia cell lines (GANMO-1 and CMK11-5) was determined by 4-hour ^{51}Cr-release assays at an E/T ratio of 2.5:1 in the presence or absence of anti–HLA class I MoAb or anti–HLA-DR MoAb. (D) Cold target inhibition assays. ^{51}Cr-labeled GANMO-1 cells (5×10^3 cells) were mixed with various numbers of ^{51}Cr-unlabeled Aur-$A_{207-215}$ peptide–loaded autologous LCL cells (○) or with ^{51}Cr-unlabeled Aur-$A_{207-215}$ peptide–loaded HLA-A*0201–negative allogeneic LCL cells (●). The cytotoxicity of AUR-1 to the mixture of ^{51}Cr-labeled and unlabeled target cells was determined by 4-hour ^{51}Cr-release assays at an effector-to-^{51}Cr-labeled target cell ratio of 10:1.

patients with CML in chronic phase after therapy with interferon or imatinib and 2 healthy individuals. Since we were unable to detect Aur-A–specific CTL precursors when freshly isolated lymphocytes were used for assays, PBMCs were stimulated with Aur-$A_{207-215}$ peptide and then analyzed. Representative data of tetramer assays for HLA-A*0201–positive and HLA-A*2402–positive patients with leukemia are shown in Figure 5A. The frequencies of Aur-$A_{207-215}$–specific CTL precursors in HLA-A*0201–positive and HLA-A*2402–positive patients with leukemia and healthy individuals are summarized in Figure 5B. Consequently, Aur-$A_{207-215}$–specific CTL precursors were apparently detected in both HLA-A*0201–positive and HLA-A*2402–positive patients with leukemia. The frequency of Aur-$A_{207-215}$–specific CTL precursors in leukemia patients appeared to be significantly higher than that in healthy individuals (0.25% ± 0.1% for leukemia patients, and 0.05% ± 0.03% for healthy individuals; $P < .001$). These data strongly suggest that Aur-A–specific CTL precursors are primed in patients with leukemia, and that vaccination with Aur-A peptide may efficiently induce an Aur-A–specific immune response in leukemia patients. To determine whether Aur-$A_{207-215}$–specific CTL precursors detected by tetramer assays are indeed functional, we performed tetramer assays and ELISPOT assays using the same samples simultaneously, and determined the correlation between the 2 sets of data. PBMCs isolated from 7 HLA-A*0201– or HLA-A*2402–positive individuals were used for tetramer assays and ELISPOT assays. Consequently, the frequencies of Aur-$A_{207-215}$ peptide–specific CTL precursors detected by these 2 different assay systems appeared to be closely correlated

From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.



Figure 3. Expression of Aur-A in freshly isolated leukemia cells and the cytotoxicity of AUR-1 against freshly isolated leukemia cells. (A) Expression of *Aur-A* mRNA in freshly isolated leukemia cells, normal PBMCs, and PHA-stimulated T lymphocytes. Expression levels of *Aur-A* mRNA in freshly isolated leukemia cells and normal cells were determined using samples obtained from 7 patients with ALL, 17 patients with AML, 10 patients with CML in chronic phase, 4 healthy individuals, and PHA-stimulated T lymphoblasts obtained from 3 healthy individuals. To prepare PHA-stimulated T lymphoblasts, PBMCs were cultured in RPMI 1640 medium supplemented with 10% FCS and PHA at an appropriate concentration for 4 days. The level of *Aur-A* mRNA in normal PBMCs is shown as 1.0 and the expression levels in samples were calculated relative to this value. (B) Cytotoxicity of AUR-1 against freshly isolated leukemia cells and normal cells. The cytotoxicity of AUR-1 against HLA-A*0201–positive and HLA-A*0201–negative freshly isolated leukemia cells, HLA-A*0201–positive normal PBMCs, and HLA-A*0201–positive normal PHA-stimulated T lymphoblasts was determined by ^{51}Cr-release assays at E:T ratios of 20:1, 10:1, and 5:1. Expression levels of *Aur-A* mRNA in samples are also shown.

(r = 0.817; Figure S1B). These data strongly suggest that Aur-A tetramer–positive cells certainly have a functional response to stimulation with Aur-A.

Discussion

In the present study, we demonstrated that Aur-A is an ideal target antigen of cellular immunotherapy for leukemia, based on the following findings. First, Aur-A is broadly overexpressed in various types of leukemia but not in normal tissues except for testis, which is negative for HLA expression. Second, an Aur-A–derived peptide, Aur-$A_{207-215}$, can bind to HLA-A*0201 and HLA*2402 molecules and elicit Aur-A–specific CTLs. Third, Aur-A is efficiently processed in leukemia cells, and leukemia cell lines and freshly isolated leukemia cells, but not normal cells, are lysed by Aur-A–specific CTLs in an HLA class I–restricted manner. Fourth, Aur-A–specific CTL precursors are certainly present in the peripheral blood of patients with leukemia.

One of the important characteristics of proteins that could be used as ideal tumor-associated antigens for cancer immunotherapy is an essential role in tumorigenesis and/or tumor progression. Aur-A is localized mainly at spindle poles and the mitotic spindle during mitosis, where it regulates the functions of centrosomes, spindles, and kinetochores required for proper mitotic progression. Recent studies have revealed that Aur-A is frequently overexpressed in various cancer cells, indicating its involvement in tumorigenesis.[9-14] Overexpression of Aur-A contributes to genetic instability and tumorigenesis by disrupting the proper assembly of the mitotic checkpoint complex at the level of the Cdc20-BubR1 interaction.[34] Its overexpression also causes resistance to apoptosis induced by taxol in human cancer cell lines.[35,36] Moreover, Aur-A is a key regulatory component of the p53 pathway, as its overexpression leads to increased p53 degradation, thus facilitating oncogenic transformation.[37] In addition, Aur-A expression in tumors is often associated with poor histologic differentiation and poor prognosis.[12-14] These characteristics indicate that Aur-A is an ideal target antigen for cancer immunotherapy. Although Aur-A is also expressed in normal cells during mitosis, its expression level in normal tissue is quite low; therefore, normal mitotic cells are resistant to Aur-A–specific CTL-mediated cytotoxicity, as shown in the present study.

From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.



Figure 4. Expression of Aur-A in CD34$^+$CD38^{low} fractions of CML cells and normal hematopoietic progenitor cells, and cytotoxicity of AUR-1 against CD34$^+$ CML cells and CD34$^+$ normal hematopoietic stem cells. (A) Expression levels of *Aur-A* mRNA in CD34$^+$ cells isolated from BMMCs of patients with CML, CD34$^+$ cells isolated from normal BMMCs and CBMCs, and normal PBMCs. Expression levels of *Aur-A* mRNA in leukemic CD34$^+$ cells, normal hematopoietic stem cells, and normal PBMCs were determined using 3 samples of CML BMMCs, 1 sample of normal BMMCs, 2 samples of CBMCs, and 4 samples of normal PBMCs. The level of *Aur-A* mRNA in normal PBMCs is shown as 1.0 and the expression levels in samples were calculated relative to this value. (B) Representative data of *Aur-A* mRNA expression in the CD34$^+$CD38^{low} fraction of BMMCs, whole BMMCs, and PBMCs isolated from a patient with CML in chronic phase and PBMCs isolated from 4 healthy individuals. The CD34$^+$CD38^{low} cells were collected using a cell sorter. (C) Representative data of *Aur-A* mRNA expression in the CD34$^+$CD38^{low} fraction of CBMCs isolated from a normal donor and PBMCs isolated from 4 healthy individuals. The CD34$^+$CD38^{low} cells were collected using a cell sorter. (D) Cytotoxicity of AUR-1 against CD34$^+$ leukemia progenitor cells and normal CD34$^+$ hematopoietic progenitor cells. The cytotoxicity of AUR-1 against CD34$^+$ leukemia cells isolated from 2 HLA-A*0201–positive patients with CML and normal CD34$^+$ hematopoietic progenitor cells isolated from an HLA-A*0201–positive cord blood donor was determined by ^{51}Cr-release assays at E/T ratios of 20:1, 10:1, and 5:1. Expression levels of *Aur-A* mRNA in samples are also shown.

As reported previously,[17-19] the present study demonstrated that Aur-A is overexpressed widely in various types of leukemia including AML, ALL, and CML. Among the leukemias, CML cells appeared to express a large amount of Aur-A. It was also found that Aur-A is abundantly expressed in the CD34$^+$CD38^{low} fraction of CML cells. Previous gene expression profiling analysis has also shown that mitogen-activated protein kinases, which activate mitotic kinases including Aurora kinases, are overexpressed in

From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.



Figure 5. Detection of Aur-$A_{207-215}$–specific CTL precursors in patients with leukemia. (A) Representative data of the tetramer assay for Aur-$A_{207-215}$–specific CTL precursors. PBMCs isolated from HLA-A*0201–positive and HLA-A*2402–positive patients with CML in chronic phase were stimulated with Aur-$A_{207-215}$ peptide and then stained with HLA-A*0201/Aur-$A_{207-215}$ tetramer and HLA-A*2402/Aur-$A_{207-215}$ tetramer, respectively. HLA-A*0201/HIV-1 p17 Gag_{77-85} (SLYNTVATL) tetramer and HLA-A*2402/HIV-1 $Env_{584-592}$ (RYLRDQQLL) tetramer were used as negative controls. (B) Summary of tetramer assays for Aur-$A_{207-215}$–specific CTL precursors. PBMCs isolated from 3 HLA-A*0201–positive patients with leukemia (a patient with AML in complete remission after allogeneic stem cell transplantation, a patient with ALL in complete remission after chemotherapy, and a patient with untreated CML in chronic phase; ■), 2 HLA-A*2402–positive patients with leukemia (2 patients with CML in chronic phase after therapy with interferon or imatinib; ▲), 8 HLA-A*0201–positive healthy individuals (□), and 2 HLA-A*2402–positive healthy individuals (△) were stained with HLA-A*0201/Aur-$A_{207-215}$ or HLA-A*2402/Aur-$A_{207-215}$ tetramer. The frequency of Aur-$A_{207-215}$–specific CTL precursors in the patients with leukemia was significantly higher than that in healthy individuals (Student *t* test; $P < .001$).

$CD34^+$ progenitor cells in CML.[38] In contrast to overexpression of Aur-A in the $CD34^+CD38^{low}$ fraction of CML cells, the expression level of Aur-A in the $CD34^+CD38^{low}$ fraction of normal hematopoietic progenitors appeared to be markedly lower than that in leukemic cells. We therefore addressed the question of whether Aur-A–specific CTLs can lyse leukemic progenitors. Because a sufficient number of $CD34^+CD38^{low}$ cells could not be obtained, $CD34^+$ cells were used as target cells. Consequently, in parallel with the expression levels of Aur-A, $CD34^+$ CML cells but not $CD34^+$ normal hematopoietic progenitor cells were efficiently lysed by Aur-A–specific CTLs. Although the detailed characteristics of leukemic stem cells are still obscure, they are considered to be present in the $CD34^+CD38^{low}$ fraction.[39-41] Taken together, targeting of Aur-A may be effective for eradicating leukemic stem cells.

Another interesting finding of this study was that Aur-$A_{207-215}$ peptide is able to bind to HLA-A*2402 as well as to HLA-A*0201. Although AUR-1 could not recognize the complex of Aur-$A_{207-215}$ peptide and HLA-A*0206 or HLA-A*0207, this peptide can bind to the HLA-A*0206 molecule (data not shown; written communication from Dr K. Udaka, Kochi University, Nangoku, Japan, August 5, 2007). Binding of a single peptide to both HLA-A*0201 and HLA-A*2402 has also been reported previously for a WT1-derived peptide ($WT1_{235-243}$; CMTWNQMNL),[30,42] which is now used as a cancer peptide vaccine. Since CTLs recognize a tumor-associated epitope in the context of HLA class I molecules, identification of a peptide that can bind to common HLA types is essential for development of a universal cancer peptide vaccine. Because HLA-A*2402 is the most common HLA type in the Japanese population, Aur-$A_{207-215}$ is a promiscuous peptide and therefore likely useful for development of a cancer vaccine for Asian as well as white patients.

To date, 3 Aurora kinases, Aur-A, Aur-B, and Aur-C, have been identified in mammals. The Aurora kinases show different subcellular localization patterns and perform distinct tasks during cell division.[43] These molecules show a similar domain organization: a N-terminal domain of 39-129 residues, a protein kinase domain, and a short C-terminal domain of 15-20 residues. The N-terminal domain of Aurora kinases shows low sequence conservation, and this determines selectivity during protein-protein interactions.[44] In contrast, the catalytic domain is more highly conserved. Importantly, Aur-$A_{207-215}$ is located in the catalytic domain and the conserved residues of Aur-A, Aur-B, and Aur-C (Figure S2). Interestingly, the Aur-$B_{149-157}$, Aur-$B_{151-159}$, and Aur-C_{83-91} peptides, which are derived from the catalytic domain of Aur-B and Aur-C, can bind to HLA-A*0201 and HLA*2402 molecules (Figure S3), suggesting that these residues could be a universal target epitope for cancer immunotherapy.

In summary, we have demonstrated for the first time that Aur-A is a potentially ideal target of cellular immunotherapy for leukemia. When considering the evidence that Aur-A is overexpressed widely in various kinds of cancer, Aur-A–targeting cancer immunotherapy may be universally applicable. On the basis of our present data, we are now planning a clinical trial of Aur-A peptide vaccination for cancer patients.

Acknowledgments

We are grateful for the skilled technical assistance of Ms Junko Mizumoto and Dr Kenji Kameda, Ehime University (Toon, Japan). We thank Dr A. John Barrett, NHLBI/NIH (Bethesda, MD), for providing the C1R-A*0201 cell line. We also thank Dr Hiroo Saji, HLA Laboratory, Japan, for HLA typing.

This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan; a Grant-in-Aid for Cancer Research (no. 19-14) from the Ministry of Health, Labor and Welfare; and from the Uehara Memorial Foundation.

Authorship

Contribution: T.O. and H.F. designed and performed the research and wrote the paper; K.S., T.A., Y.Y., and T.H. discussed and interpreted the experimental results and provided clinical materials; K.K. made and supplied the tetramer; and M.Y. designed the research, wrote and edited the paper, and provided financial support.

From www.bloodjournal.org by YOSHIKI AKASTSUKA on March 18, 2009. For personal use only.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Masaki Yasukawa, Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan; e-mail: yasukawa@m.ehime-u.ac.jp.

References

1. Rosenberg SA, Yang JC, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
2. Barrett AJ, Rezvani K. Translational mini-review series on vaccines: peptide vaccines for myeloid leukemias. Clin Exp Immunol. 2007;148:189-198.
3. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101:13885-13890.
4. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236-242.
5. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene. 1997; 14:2195-2200.
6. Giet R, Petretti C, Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol. 2005;15:241-250.
7. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer. 2005;5:42-50.
8. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci. 2007;120: 2987-2996.
9. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17:3052-3065.
10. Sakakura C, Hagiwara A, Yasuoka R, et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer. 2001;84:824-831.
11. Li D, Zhu J, Firozi PF, et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res. 2003;9: 991-997.
12. Reiter R, Gais P, Jütting U, et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:5136-5141.
13. Landen CN Jr, Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res. 2007;13:4098-4104.
14. Guan Z, Wang XR, Zhu XF, et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res. 2007;67:10436-10444.
15. Hamada M, Yakushijin Y, Ohtsuka M, Kakimoto M, Yasukawa M, Fujita S. Aurora2/ BTAK/ STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma. Br J Haematol. 2003;121:439-447.
16. Camacho E, Beà S, Salaverría I, et al. Analysis of Aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma. Int J Cancer. 2006;118:357-363.
17. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther. 2007; 6:1851-1857.
18. Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica. 2008;93:662-669.
19. Huang XF, Luo SK, Xu J, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood. 2008;111:2854-2865.
20. Zhou H, Kuang J, Zhong L, et al. Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998;20:189-193.
21. Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in $p53^{-/-}$ cells. EMBO J. 2002;21:483-492.
22. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res. 2005;65:2899-2905.
23. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res. 2006;12:6869-6875.
24. Shi Y, Reiman T, Li W, et al. Targeting aurora kinases as therapy in multiple myeloma. Blood. 2007;109:3915-3921.
25. Tyler RK, Shpiro N, Marquez R, Eyers PA. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle. 2007;6:2846-2854.
26. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A. 2007;104:4106-4111.
27. Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007;110:2034-2040.
28. Kuzushima K, Hayashi N, Kimura H, Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific $CD8^+$ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood. 2001;98:1872-1881.
29. Suemori K, Fujiwara H, Ochi T, et al. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes. Cancer Sci. 2008;99:1414-1419.
30. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a $CD8^+$ cytotoxic T-lymphocyte specific for WT1 peptide. Blood. 2000;95:286-293.
31. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific $CD4^+$ as well as $CD8^+$ cytotoxic T lymphocytes in humans. Blood. 2000;95:2352-2355.
32. Kuzushima K, Hayashi N, Kudoh A, et al. Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific $CD8^+$ T cells. Blood. 2003;101:1460-1468.
33. Azuma T, Otsuki T, Kuzushima K, Froelich CJ, Fujita S, Yasukawa M. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2004;10:7402-7412.
34. Ke YW, Dou Z, Zhang J, Yao XB. Function and regulation of Aurora/Ip11p kinase family in cell division. Cell Res. 2003;13:69-81.
35. Anand S, Penrhyn-Lowe S, Venkitaraman AR. Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003;3:51-62.
36. Jiang Y, Zhang Y, Lees E, Seghezzi W. AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer. Oncogene. 2003;22:8293-8301.
37. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004;36:55-62.
38. Diaz-Blanco E, Bruns I, Neumann F, et al. Molecular signature of $CD34^+$ hematopoietic and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21:494-504.
39. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-648.
40. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-737.
41. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood. 2000;95:1007-1013.
42. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 2002;100:3835-3837.
43. Bolanos-Garcia VM. Aurora kinases. Int J Biochem Cell Biol. 2005;37:1572-1577.
44. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol. 2003;4:842-854.

ASBMT
American Society for Blood and Marrow Transplantation

Exploration of the Genetic Basis of GVHD by Genetic Association Studies

Seishi Ogawa,[1,2] Aiko Matsubara,[1,2] Makoto Onizuka,[3] Koichi Kashiwase,[4] Masashi Sanada,[1,2] Motohiro Kato,[1,2] Yasuhito Nannya,[2] Yoshiki Akatsuka,[5] Masahiro Satake,[4] Junko Takita,[1,2] Shigeru Chiba,[6] Hiroo Saji,[7] Etsuko Maruya,[7] Hidetoshi Inoko,[3] Yasuo Morishima,[5] Yoshihisa Kodera,[8] Sasazuki Takehiko[9] On behalf of the Japan Marrow Donation Program (JMDP)

INTRODUCTION

Graft-versus-host disease (GVHD), as well as graft-versus-leukemia effect (GVL), are essentially allo-immune reactions, which are induced by the engrafted donor T cells that recognize the host-derived allo-antigens presented on their targets (Figure 1). In HLA-matched transplantation, these antigens are called minor histocompatibility antigens (mHags), and are typically defined by the host single nucleotide polymorphisms (SNPs) that are not shared by the donor and therefore considered to be genetically mismatched between the donor and the recipient [1–3]. Thus, the development of both allo-reactions absolutely depends on the presence of 1 or more mismatched mHags, although these reactions could be further modified by other genetic as well as environmental factors, including, cytokine polymorphisms and GVHD prophylaxis. So, in view of better preventing GVHD and specifically targeting allo-immunity to the tumor component, central questions are what mHAgs are responsible for the development of GVHD or GVL and what genetic factors can influence the overall reactions, which are the plausible targets of genome-wide association studies (GWAS) [4-8].

To identify the genetic basis of GVHD, we conducted GWAS by genotyping more than 500,000 SNPs using Affymetrix GeneChip platforms [9,10] in donors and recipients from 1,598 unrelated transplants performed through the Japan Marrow Donor Program (JMDP). All transplants were matched for HLA-A, B, C, DRB1, and DQB1 by high-resolution DNA typing, while 1033 (63%) transplants were mismatched for HLA-DPB1. Six hundred fifty-six (41.7%) and 245 (14.9%) of transplants had developed grade II-IV and grade III-IV of acute GVHD (aGVHD), respectively. Overall SNP call rates exceeded 98% both in donors and in recipients. Unobserved HapMap PhaseII SNPs were rigorously imputed from the genotyped SNPs [11-13]. After excluding those disqualified SNPs showing <95% call rate, deviation from Hardy-Weinberg equilibrium, or <5% minor allele frequency, 1,276,699 SNPs were tested for association with development of aGVHD and chronic GVHD (cGVHD), relapse, and overall survival (OS), by calculating log-rank statistics for each SNP. Statistical thresholds for genome-wide *P* value of .05 were determined empirically by doing 1,000 permutations for each analysis. Association tests were performed with regard to the simple genotype of donor and recipient SNPs. Alternatively, to identify possible mHag loci, GWAS were performed based on the allele-mismatch defined for each SNP locus, rather than simple SNP genotypes in donors and recipients. In the latter setting, associations were tested within the subgroups that shared particular HLA-types based on HLA-restriction. Generally speaking, the sample size of ~1,600 transplants in the current study was relatively small compared to the size of typical GWAS studies, and it was further reduced in the subgroup analysis [8]. Thus, it was likely that we could find only those mHag loci that were restricted to major HLA alleles and whose allele-mismatch conferred strong genetic effects on the development of GvHD [14,15]. However, this did not necessarily preclude conducting the current study, because it was such mHags that are thought to be clinically relevant.

From the [1]Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Japan; [2]University of Tokyo, Tokyo, Japan; [3]Tokai University, Isehara, Japan; [4]Tokyo Metroporitan Red Cross Blood Center, Tokyo, Japan; [5]Aichi Cancer Center, Nagoya, Japan; [6]Tsukub University, Tsukub, Japan; [7]NPO HLA Laboratory, Kyoto, Japan; [8]Aichi Medical Universiry, Aichi, Japan; and [9]International Medical Center of Japan, Tokyo, Japan.

Financial disclosure: See Acknowledgments on page 41.

Correspondence and reprint requests: Seishi Ogawa, MD, PhD, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan (e-mail: sogawa-tky@umin.ac.jp).

1083-8791/09/151S-0001$36.00/0
doi:10.1016/j.bbmt.2008.11.020



Figure 1. Allo-immunity plays central roles in HSCT.

In the analysis regarding genotype mismatch for aGVHD under the assumption of no HLA restriction, SNPs around the HLA-DPB1 locus showed strong association with the development of grade II-IV aGVHD with the maximum P value of 1.81×10^{-9} at rs6937034, and thus, the GWAS successfully captured the association of HLA-DPB1 allele mismatch as directly defined by high-resolution DNA typing (hazard ratio [HR] = 1.91, $P = 2.88 \times 10^{-13}$) (Figure 2) [16]. No other loci were identified that were significantly associated with aGVHD under the assumption of no HLA restrictions. To identify the target mHags for aGVHD, we further performed subgroup analyses, in which the analysis were confined to those transplants sharing major HLA types among the Japanese population [17]. Six loci were identified as candidate mHag loci. rs17473423 on chr12 was associated with the A*2402/B*5201/Cw*1201/DRB1*1501/DQB1*0601, which represents the most prevalent HLA haplotype among the Japanese population and shared in ~40% of unrelated transplants in Japanese (grade III-IV aGVHD, with maximum $P = 3.99 \times 10^{-13}$) (Figures 2b and 3b). rs9657655 on chr9 was associated with another common haplotype in Japanese, A*3303/B*4403/Cw*1403 (grade III-IV aGVHD with maximum $P = 8.56 \times 10^{-10}$) (Figures 2c and 3b). We found additional 4 loci that were associated with DQB1*0501, Cw*0102, B*5201, and Cw*1202. We also tested the association of GVHD with simple genotype in either recipients or donors, though which 2 recipient SNPs were found to be associated with aGVHD, rs5998746 on chr22 ($P = 3.41 \times 10^{-8}$) and rs11873016 on chr18 ($P = 1.26 \times 10^{-8}$), whereas no donor SNPs showed significant associations. Similarly, we identified 4 candidate SNPs associated with the development of severe cGVHD or relapse.

Our study provided a unique opportunity, in that a combination of 2 different genotypes, rather than mere genotypes in single individuals, is explored for association with particular disease phenotypes through whole genome association scanning. Although further replication studies and biologic confirmation are



Figure 2. Representative results of GWAS based on genotype mismatch. $-\log_{10}P$ values are plotted in genetic order. Results are presented for association tests for genotype mismatch under no HLA restriction (A), and under the restriction to HLA DQB1*0601 (B) and HLA B*4403 (C).



Figure 3. QQ-plots of the statistics. QQ-plots of the analysis of genotype mismatch under no restriction on HLA (A), and restriction to HLA DQB1*0601 (B) and HLA B*4403 (C) where observed test statistics values are plotted against expected values from 1000 random permutations (red); 95% confidence intervals are also provided by shadows. Only the plots for the top 20,000 results are presented. The QQ-plots excluding the SNPs that belong to the positive peak are also depicted in blue.

required, our results suggest that whole genome association studies of allo-SCT could provide a novel clue to our understanding of the genetic basis of GVHD.

ACKNOWLEDGMENTS

Financial disclosure: The authors have nothing to disclose.

REFERENCES

1. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. *Nat Rev Cancer*. 2004;4:371-380.
2. Shlomchik WD. Graft-versus-host disease. *Nat Rev Immunol*. 2007;7:340-352.
3. Brickner AG. Mechanisms of minor histocompatibility antigen immunogenicity: the role of infinitesimal versus structurally profound polymorphisms. *Immunol Res*. 2006;36:33-41.
4. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases and complex traits. *Nat Rev Genet*. 2005;6:95-108.
5. Kruglyak L. The road to genome-wide association studies. *Nat Rev Genet*. 2008;9:314-318.
6. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat Rev Genet*. 2008;9:356-369.
7. Xavier RJ, Rioux JD. Genome-wide association studies: a new window into immune-mediated diseases. *Nat Rev Immunol*. 2008;8:631-643.
8. Topol EJ, Murray SS, Frazer KA. The genomics gold rush. *JAMA*. 2007;298:218-221.
9. Kennedy GC, Matsuzaki H, Dong S, et al. Large-scale genotyping of complex DNA. *Nat Biotechnol*. 2003;21:1233-1237.
10. Matsuzaki H, Dong S, Loi H, et al. Genotyping over 100,000 SNPs on a pair of oligonucleotide arrays. *Nat Methods*. 2004;1:109-111.
11. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature*. 2007;449:851-861.
12. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet*. 2007;39:906-913. 2007.
13. TheinternationlaHapMapconsortium. A haplotype map of the human genome. *Nature*. 2005;437:1299-1320.
14. Pe'er I, de Bakker PI, Maller J, Yelensky R, Altshuler D, Daly MJ. Evaluating and improving power in whole-genome association studies using fixed marker sets. *Nat Genet*. 2006;38:663-667.
15. Nannya Y, Taura K, Kurokawa M, Chiba S, Ogawa S. Evaluation of genome-wide power of genetic association studies based on empirical data from the HapMap project. *Hum Mol Genet*. 2007;16:3494-3505.
16. Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. *Biol Blood Marrow Transplant*. 2007;13:315-328.
17. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. *Tissue Antigens*. 2000;56:522-529.

Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia

Yoshiko Atsuta,[1] Ritsuro Suzuki,[1] Tokiko Nagamura-Inoue,[2] Shuichi Taniguchi,[3] Satoshi Takahashi,[4] Shunro Kai,[5] Hisashi Sakamaki,[6] Yasushi Kouzai,[7] Masaharu Kasai,[8] Takahiro Fukuda,[9] Hiroshi Azuma,[10] Minoko Takanashi,[11] Shinichiro Okamoto,[12] Masahiro Tsuchida,[13] Keisei Kawa,[14] Yasuo Morishima,[15] Yoshihisa Kodera,[16] and Shunichi Kato,[17] for the Japan Marrow Donor Program and the Japan Cord Blood Bank Network

[1]Department of Hematopoietic Stem Cell Transplantation Data Management, Nagoya University School of Medicine, Nagoya; [2]Department of Cell Processing & Transfusion, Research Hospital, Institute of Medical Science, University of Tokyo, and Tokyo Cord Blood Bank, Tokyo; [3]Department of Hematology, Toranomon Hospital, Tokyo; [4]Department of Molecular Therapy, Institute of Medical Science, University of Tokyo, Tokyo; [5]Department of Transfusion Medicine, Hyogo College of Medicine, Nishinomiya; [6]Division of Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo; [7]Department of Transfusion Medicine, Tokyo Metropolitan Fuchu Hospital, Tokyo; [8]Department of Hematology, Sapporo Hokuyu Hospital, Sapporo; [9]Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo; [10]Hokkaido Red Cross Blood Center, Sapporo; [11]Japanese Red Cross Tokyo Blood Center, Tokyo; [12]Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo; [13]Ibaraki Children's Hospital, Mito; [14]Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi; [15]Aichi Cancer Center Hospital, Nagoya; [16]BMT Center, Japanese Red Cross Nagoya First Hospital, Nagoya; and [17]Department of Cell Transplantation & Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan

We made a disease-specific comparison of unrelated cord blood (CB) recipients and human leukocyte antigen allele–matched unrelated bone marrow (BM) recipients among 484 patients with acute myeloid leukemia (AML; 173 CB and 311 BM) and 336 patients with acute lymphoblastic leukemia (ALL; 114 CB and 222 BM) who received myeloablative transplantations. In multivariate analyses, among AML cases, lower overall survival (hazard ratio [HR] = 1.5; 95% confidence interval [CI], 1.0-2.0, *P* = .028) and leukemia-free survival (HR = 1.5; 95% CI, 1.1-2.0, *P* = .012) were observed in CB recipients. The relapse rate did not differ between the 2 groups of AML (HR = 1.2; 95% CI, 0.8-1.9, *P* = .38); however, the treatment-related mortality rate showed higher trend in CB recipients (HR = 1.5; 95% CI, 1.0-2.3, *P* = .085). In ALL, there was no significant difference between the groups for relapse (HR = 1.4, 95% CI, 0.8-2.4, *P* = .19) and treatment-related mortality (HR = 1.0; 95% CI, 0.6-1.7, *P* = .98), which contributed to similar overall survival (HR = 1.1; 95% CI, 0.7-1.6, *P* = .78) and leukemia-free survival (HR = 1.2; 95% CI, 0.9-1.8, *P* = .28). Matched or mismatched single-unit CB is a favorable alternative stem cell source for patients without a human leukocyte antigen–matched related or unrelated donor. For patients with AML, decreasing mortality, especially in the early phase of transplantation, is required to improve the outcome for CB recipients. (Blood. 2009;113:1631-1638)

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) with bone marrow (BM) or peripheral blood, the curative treatment of choice for acute leukemia, is limited by the inadequate supply of human leukocyte antigen (HLA)–identical related donors. Bone marrow from HLA-matched unrelated donors has been a major alternative graft source.[1-3] Umbilical cord blood (CB), an alternative stem cell source to BM or peripheral blood stem cells, has been used primarily in children,[4-10] but its use in adults is increasing.[11,12]

Clinical comparison studies of cord blood transplantation (CBT) and bone marrow transplantation (BMT) for leukemia from unrelated donors in adult recipients showed comparable outcomes.[11-13] Recipients of CBT showed delayed neutrophil recovery and lower incidence of acute graft-versus-host disease (GVHD).[11-13] Overall treatment-related mortality (TRM) was reported to be similar[12] or higher[11] compared with HLA-matched BM. Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are different disease entities that require different chemotherapy regimens for treatment. However, previous comparison studies have included both diseases because of limitation in the number of CBTs given to adults.

In addition, the study periods of previous studies encompass the pioneering period of CBT, when the general practice was to use these grafts in patients in whom there were no other curative options and when the relevance of cell dose and HLA matching had not yet been recognized.[6,7,14]

Accumulation of a larger number of CBT results enabled us to make a controlled comparison with unrelated BMTs. To avoid the inclusion of the pioneering period of CBT, the subjects were limited to those who received transplantations in and after 2000.

Methods

Collection of data and data source

The recipients' clinical data were provided by the Japan Cord Blood Bank Network (JCBBN) and the Japan Marrow Donor Program (JMDP).[15]

Submitted March 21, 2008; accepted November 14, 2008. Prepublished online as *Blood* First Edition paper, December 22, 2008; DOI 10.1182/blood-2008-03-147041.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2009 by The American Society of Hematology

Peripheral blood stem cell donation from unrelated donors is not permitted in Japan. All 11 CB banks in Japan are affiliated to JCBBN. Both JCBBN and JMDP collect recipients' clinical information at 100 days after transplantation. Patients' information on survival, disease status, and long-term complications, including chronic GVHD and second malignancies, are renewed annually by follow-up forms. This study was approved by the data management committees of JMDP and JCBBN.

Patients

Between January 2000 and December 2005, a total of 1690 adult patients at least 16 years of age with acute leukemia (999 AML, 261 CB and 738 BM; and 691 ALL, 178 CB and 513 BM) received first HSCT with myeloablative conditioning either CB or BM from unrelated donors. Of these, patients who received a single CB unit with 0 to 2 HLA mismatches, or HLA-A, -B, -C, and DRB1 allele-matched BM from unrelated donors were analyzed. HLA matching of CB was performed using low-resolution molecular typing methods for HLA-A and -B, and high-resolution molecular typing for HLA-DRB1. Of 1023 BM recipients with complete HLA high-resolution data, the following recipients with HLA HLA-A, -B, -C, and DRB1 allele mismatches were excluded: 306 recipients with 1 of 8 mismatches (39 for HLA-A, 6 for HLA-B, 137 for HLA-C, and 124 for HLA-DRB1), 150 recipients with 2 of 8 mismatches (36 for 2 class I antigens, and 114 for class I and class II antigens), 33 recipients with 3 of 8 mismatches, and 1 recipient with 4 of 8 mismatches. Of 390 recipients of CB with complete HLA data, 95 recipients with 3 mismatches and 8 patients with 4 mismatches were excluded. A total of 484 patients with AML (173 CBTs and 311 BMTs) and 336 patients with ALL (114 CBTs and 222 BMTs) were the subjects for the analyses. Eighty-five centers performed 287 CBTs analyzed in this study, and 114 centers performed 533 BMTs.

Definitions

Neutrophil recovery was defined by an absolute neutrophil count of at least 500 cells/mm^3 for 3 consecutive points; platelet recovery was defined by a count of at least 50 000 platelets/mm^3 without transfusion support. Diagnosis and clinical grading of acute GVHD were performed according to the established criteria.[16] Relapse was defined as a recurrence of underlying hematologic malignant diseases. Treatment-related death was defined as death during a continuous remission. Leukemia-free survival (LFS) was defined as survival in a state of continuous remission.

Statistical analysis

Separate analyses were performed for AML and ALL. Descriptive statistical analysis was performed to assess patient baseline characteristics, diagnosis, disease classification, disease status at conditioning, donor-patient ABO mismatches, preparative regimen, and GVHD prophylaxis. The 2-sided χ^2 test was used for categorical variables, and the 2-sided Wilcoxon rank sum test was used for continuous variables. Cumulative incidence curves were used in a competing-risks setting to calculate the probability of neutrophil and platelet recovery, acute and chronic GVHD, relapse, and TRM.[17] For neutrophil and platelet recovery, death before neutrophil or platelet recovery was the competing event; for GVHD, death without GVHD and relapse were the competing events; for relapse, death without relapse was the competing event; and, for TRM, relapse was the competing event. Gray test was used for group comparison of cumulative incidence.[18] Overall survival (OS) and LFS were calculated using the Kaplan-Meier method. The log-rank test was used for group comparisons. Adjusted comparison of the stem cell source on OS and LFS was performed with the use of the Cox proportional-hazards regression model. For other outcomes, the Fine and Gray proportional-hazards model for subdistribution of a competing risk was used.[19] Adjusted probabilities of OS and DFS were estimated using the Cox proportional-hazards regression model, with consideration of other significant clinical variables in the final multivariate models. The variables considered were the patient's age at transplantation, patient's sex, donor-patient sex mismatch, donor-patient ABO mismatch, disease status at conditioning, and t(9;22) chromosome abnormality or others for ALL, cytogenetic information and French-American-British (FAB) classification of M5/M6/M7 or others for AML, the conditioning regimen, and the type of prophylaxis against GVHD. Factors differing in distribution between CB and BM recipients ($P < .10$) and factors known to influence outcomes (such as patient age at transplantation and chromosome abnormalities and FAB classification of leukemia) were included in the final models. Variables with more than 2 categories were dichotomized for the final multivariate model. The cutoff points of the variables were chosen to make optimal use of the information, with the proviso that smaller groups contain at least 20% of the patients. Variables were dichotomized as follows: patient age greater or younger than 45 years at transplantation, female donor to male recipient donor-recipient sex mismatch versus others for donor-recipient sex matching, donor-recipient ABO major mismatch versus others for ABO matching, M5/M6/M7 FAB classification versus others for classification of AML, chromosome abnormality other than favorable abnormalities for cytogenetics of AML, cyclophosphamide and total body irradiation (TBI) or busulfan and cyclophosphamide or others for conditioning regimen of AML, cyclophospohamide and TBI, or others for conditioning regimen of ALL, and cyclosporine-based versus tacrolimus-based prophylaxis against GVHD. Disease status at transplantation was categorized as first complete remission (1CR), second or later complete remission (2CR), or more advanced disease; which was included in the final model using dichotomized dummy variables. All P values were 2-sided.

The statistical power to detect hazard ratios (HRs) of 2.0 and 1.5 (a regression coefficient equal to 0.6931 and 0.4055, respectively) on Cox regression of the log hazard ratio at a .05 significance level adjusted for event rate were 99% and 78%, respectively, for 484 patients with AML and 97% and 60%, respectively, for 336 patients with ALL. The levels of statistical power for subgroup analyses were as follows: 54% and 22% for 1CR, 51% and 21% for 2CR, 96% and 58% for more advanced in AML patients, 62% and 26% for 1CR, 47% and 20% for 2CR, and 67% and 29% for more advanced in ALL patients.[20]

Results

Patient characteristics

The characteristics of the patients are shown in Table 1. There was no significant difference in recipients' age at transplantation in AML (median age, CB vs BM = 38 vs 38 years, $P = .61$) and in ALL (median age, CB vs BM = 34 vs 32 years, $P = .29$). The female/male ratio was higher (CB vs BM = 54% vs 38% in AML patients, and CB vs BM = 54% vs 38% in ALL patients, $P < .001$ and $P = .005$, respectively) in CB recipients, resulting in the lower donor-patient sex match rate (CB vs BM = 48% vs 69% in AML patients, and CB vs BM = 46% vs 65% in ALL patients, $P < .001$ and $P = .002$, respectively) in CB recipients. The proportion of ALL patients with Philadelphia chromosome abnormality was higher (CB vs BM = 38% vs 23%) in CB recipients. CB recipients were likely to have more advanced disease status at transplantation (relapse or induction failure, CB vs BM = 47% vs 31% in AML patients, and CB vs BM = 26% vs 19% in ALL patients), and the difference was significant in AML ($P = .003$). HLA-A, -B (low-resolution typing), and -DRB1 (high-resolution typing) was mismatched in 93% of both AML and ALL among CB recipients, whereas HLA -A, -B, -C, and -DRB1 were all genotypically matched for BM recipients. The ABO-matched donor-patient pair proportion was consistently lower for CB (CB vs BM = 34% vs 59% in AML patients and CB vs BM = 32% vs 58% in ALL patients).

A preparative regimen with TBI and cyclophosphamide was used in almost all patients, and cytosine arabinoside was supplemented for CB recipients with AML (36%) in addition to TBI and cyclophosphamide. For GVHD prophylaxis, tacrolimus (CB vs BM = 29% vs 56% in AML patients, and CB vs BM = 37% vs 53% in ALL patients) and

Table 1. Characteristics of recipients of cord blood or bone marrow from unrelated donors in 484 patients with acute myeloid leukemia and 336 patients with acute lymphoblastic leukemia

	Acute myeloid leukemia			Acute lymphoblastic leukemia		
Characteristic	**U-CBT**	**U-BMT**	***P***	**U-CBT**	**U-BMT**	***P***
No. of transplantations	173	311		114	222	
Median patient age at transplantation, y (range)	38 (16-69)	38 (16-60)	.61	34 (16-58)	32 (16-59)	.29
Patient sex, n (%)						
Male	80 (46)	194 (62)	< .001	52 (46)	137 (62)	.005
Female	93 (54)	117 (38)		62 (54)	85 (38)	
Sex matching, n (%)			< .001			.002
Matched	83 (48)	216 (69)		52 (46)	145 (65)	
Male to female	44 (25)	57 (18)		35 (31)	42 (19)	
Female to male	46 (27)	37 (12)		27 (24)	35 (16)	
Unknown	0 (0)	1 (0)		0 (0)	0 (0)	
Disease classification						
AML (French-American-British)			.045			
M0	17 (10)	26 (8)				
M1	30 (17)	38 (12)				
M2	52 (30)	88 (28)				
M3	4 (2)	25 (8)				
M4	27 (16)	55 (18)				
M5	23 (13)	41 (13)				
M6	3 (2)	18 (6)				
M7	2 (1)	5 (2)				
Others/unknown	15 (9)	15 (5)				
Cytogenetics			.042			
Favorable*	19 (11)	66 (21)				
Normal	74 (43)	116 (37)				
Other	57 (33)	95 (31)				
Unknown	23 (13)	34 (11)				
ALL cytogenetics						.022
t(9;22)				43 (38)	52 (23)	
t(4;11)				2 (2)	3 (1)	
Others				22 (19)	51 (23)	
Normal				27 (24)	85 (38)	
Unknown				20 (18)	31 (14)	
Disease status			.003			.33
First CR	50 (29)	130 (42)		63 (55)	130 (59)	
Second or after CR	39 (23)	82 (26)		21 (18)	48 (22)	
Relapse/induction failure	81 (47)	95 (31)		30 (26)	42 (19)	
Unknown	3 (2)	4 (1)		0 (0)	2 (1)	
HLA matching†						
0 mismatched loci	12 (7)			8 (7)		
1 mismatched locus	35 (20)			25 (22)		
2 mismatched loci	126 (73)			81 (71)		
ABO matching			< .001			< .001
Matched	59 (34)	185 (59)		37 (32)	128 (58)	
Minor mismatch	48 (28)	57 (18)		30 (26)	48 (22)	
Major mismatch	37 (21)	59 (19)		24 (21)	41 (18)	
Bidirectional	28 (16)	8 (3)		23 (20)	3 (1)	
Unknown	1 (1)	2 (1)		0 (0)	2 (1)	
Nucleated cells infused per 10^7/kg, median (range)	2.44 (1.65-5.49)	26.3 (2.10-58.8)	< .001	2.48 (1.51-4.06)	28.2 (2.30-79.0)	< .001
Preparative regimen			< .001			.38
CY + TBI	43 (25)	142 (46)		42 (37)	92 (41)	
CY + CA + TBI	62 (36)	41 (13)		31 (27)	53 (24)	
CY + BU + TBI	7 (4)	36 (12)		3 (3)	5 (2)	
Other TBI regimen	42 (24)	33 (11)		34 (30)	54 (24)	
BU + CY	18 (10)	55 (18)		4 (4)	12 (5)	
Other non-TBI regimen	1 (1)	4 (1)		0 (0)	6 (3)	
GVHD prophylaxisis			< .001			< .001
Cyclosporine A + sMTX	103 (60)	131 (42)		65 (57)	100 (45)	
Cyclosporine A ± other	20 (12)	4 (1)		6 (5)	3 (1)	
Tacrolimus + sMTX	34 (20)	168 (54)		26 (23)	106 (48)	
Tacrolimus ± other	15 (9)	5 (2)		16 (14)	11 (5)	
Others	1 (1)	3 (1)		1 (1)	2 (1)	

U-CBT, indicates unrelated cord blood transplantation; U-BMT, unrelated bone marrow transplantation; CR, complete remission; HLA, human leukocyte antigen; CY, cyclophosphamide; CA, cytarabine; BU, oral busulfan; TBI, total body irradiation; and sMTX, short-term methotrexate.

*Favorable abnormal karyotypes are defined as t(8;21), inv16,or t(15;17).

†Number of mismatches was counted among HLA-A, -B (low-resolution typing), and DRB1 (high-resolution typing).



Figure 1. Adjusted OS and LFS of recipients with AML or ALL of CB or BM from unrelated donors. For patients with AML, adjusted probabilities of (A) OS (CB vs BM = 48% vs 59% at 2 years, $P = .010$) and (C) LFS (CB vs BM = 42% vs 54% at 2 years, $P = .004$) were both lower in CB recipients. For patients with ALL, the adjusted probabilities of (B) OS (CB vs BM = 52% vs 53% at 2 years, $P = .99$) and (D) LFS (CB vs BM = 46% vs 44% at 2 years, $P = .41$) were similar between CB recipients and BM recipients.

short-term methotrexate (CB vs BM = 80% vs 96% in AML patients, and CB vs BM = 80% vs 93% in ALL patients) were used preferentially in BM recipients. The median follow-up period for survivors was 1.9 years (range, 0.1-6.2 years) for CB recipients and 1.4 years (range, 0.3-4.5 years) for BM recipients.

Outcome

OS. For patients with AML, the unadjusted probabilities of OS were lower for CB recipients at 1 year (51% vs 69%) and 2 years (43% vs 60%) compared with BM recipients ($P < .001$). For patients with ALL, there were no significant differences between the 2 groups (CB vs BM = 66% vs 66% at 1 year, 49% vs 57% at 2 years, $P = .40$).

Among patients with AML, the use of CB remained a significant risk factor for overall mortality after adjustment for other factors (HR = 1.5; 95% confidence interval [CI], 1.0-2.0; $P = .028$; Table 2). However, in patients with ALL, the use of CB was not a significant factor for overall mortality on multivariate analysis (HR = 1.1; 95% CI, 0.7-1.6; $P = .78$). The adjusted probability of OS was significantly lower for CB recipients (57% vs 69% at 1 year, and 48% vs 59% at 2 years, $P = .010$; Figure 1A) compared with BM recipients for patients with AML, whereas the adjusted probability of OS was similar (69% vs 64% at 1 year, and 52% vs 53% at 2 years, $P = .99$; Figure 1B) between the groups for patients with ALL.

Results of the subgroup analyses showed that the difference in survival among AML patients was prominent in patients demonstrating 1CR at transplantation (RR = 2.9, 95% CI = 1.4-6.2, $P = .005$; Table 3).

LFS. For patients with AML, the unadjusted probabilities of LFS were significantly lower for CB recipients at 1 year (43% vs 62%) and 2 years (36% vs 54%) compared with BM recipients ($P < .001$). For patients with ALL, the unadjusted probabilities of LFS were lower with marginal significance for CB recipients at 1 year (52% vs 58%) and 2 years (45% vs 51%) compared with BM recipients ($P = .06$).

Among patients with AML, the use of CB remained as a significant risk factor for treatment failure (ie, relapse or death) after adjustment for other factors (HR = 1.5; 95% CI, 1.1-2.0; $P = .012$; Table 2). However, in patients with ALL, the use of CB was not a significant factor for treatment failure by multivariate analysis (HR = 1.2; 95% CI, 0.9-1.8; $P = .28$). The adjusted probability of LFS was significantly lower for CB recipients (51% vs 62% at 1 year, and 42% vs 54% at 2 years, $P = .004$; Figure 1C) compared with BM recipients for patients with AML, whereas the adjusted probability of LFS was similar (53% vs 53% at 1 year, and 46% vs 44% at 2 years, $P = .41$; Figure 1D) between the groups for patients with ALL.

Relapse

On univariate analyses, the cumulative incidence of relapse was higher for CB recipients with marginal significance in both AML (27% vs 20% at 1 year, and 31% vs 24% at 2 years) and ALL (27% vs 19% at 1 year, and 31% vs 24% at 2 years) ($P = .067$, and .085, respectively; Figure 2A,B).

On multivariate analyses adjusted by other factors, there was no significantly higher risk of relapse for CB recipients with either AML (RR = 1.2, 95% CI = 0.8-1.9, $P = .38$) or ALL (RR = 1.4, 95% CI = 0.8-2.4, $P = .19$; Table 2).

TRM

For patients with AML, the unadjusted cumulative incidence of TRM was significantly higher for CB recipients at 1 year (30% vs 19%) and 2 years (33% vs 22%) compared with those for BM recipients ($P = .004$; Figure 2C). For patients with ALL, the

Table 2. Results of multivariate analysis of outcomes in 173 recipients of cord blood and 311 recipients of bone marrow with acute myeloid leukemia, and 114 recipients of cord blood and 222 recipients of bone marrow with acute lymphoblastic leukemia

	Acute myeloid leukemia		Acute lymphoblastic leukemia	
Outcome	**RR (95% CI)**	**P**	**RR (95% CI)**	**P**
Overall survival*				
BM	1.00		1.00	
CB	1.45 (1.04-2.01)	.028	1.06 (0.71-1.57)	.78
Leukemia-free survival†				
BM	1.00		1.00	
CB	1.48 (1.09-2.01)	.012	1.22 (0.85-1.76)	.28
Relapse‡				
BM	1.00		1.00	
CB	1.21 (0.79-1.87)	.38	1.42 (0.84-2.41)	.19
TRM§				
BM	1.00		1.00	
CB	1.47 (0.95-2.28)	.085	1.01 (0.59-1.73)	.98
Neutrophil recovery‖				
BM	1.00		1.00	
CB	0.41 (0.33-0.51)	< .001	0.37 (0.29-0.48)	< .001
Platelet recovery¶				
BM	1.00		1.00	
CB	0.34 (0.27-0.44)	< .001	0.43 (0.33-0.56)	< .001
Acute GVHD#				
BM	1.00		1.00	
CB	0.80 (0.56-1.15)	.23	0.61 (0.39-0.95)	.028
Chronic GVHD**				
BM	1.00		1.00	
CB	0.94 (0.63-1.42)	.79	1.08 (0.66-1.77)	.77
Chronic GVHD, extensive type††				
BM	1.00		1.00	
CB	0.36 (0.18-0.72)	.004	0.58 (0.28-1.20)	.14

RR indicates relative risk; CI, confidence interval; BM, bone marrow; CB, cord blood; and GVHD, graft-versus-host disease.

*For overall survival, other significant variables for AML were patient age more than 45 years at transplantation, more advanced disease status at conditioning, M5/M6/M7 French-American-British classification, and female donor to male recipient donor-recipient sex mismatch; other significant variables for ALL were second or after complete remission disease status, more advanced disease status, and Philadelphia chromosome abnormality.

†For leukemia-free survival, other significant variables for AML were patient age more than 45 years at transplantation, more advanced disease status at conditioning, M5/M6/M7 French-American-British classification, and female donor to male recipient donor-recipient sex mismatch; other significant variables for ALL were second or after complete remission disease status, more advanced disease status, and Philadelphia chromosome abnormality.

‡For relapse, other significant variables for AML were more advanced disease status at conditioning, donor-recipient ABO major mismatch, chromosome abnormality other than favorable abnormalities, and cyclophosphamide and total body irradiation or busulfan and cyclophosphamide conditioning regimen; other significant variables for ALL were second or after complete remission disease status, more advanced disease status, and cyclophosphamide and total body irradiation conditioning.

§For TRM, other significant variables for AML were patient age more than 45 years at transplantation, second or after complete remission disease status, more advanced disease status, and chromosome abnormality other than favorable abnormalities; other significant variables for ALL were patient age more than 45 years at transplantation, more advanced disease status at conditioning, and conditioning other than cyclophosphamide and total body irradiation.

‖For neutrophil recovery, other significant variables for AML were second or after complete remission disease status and more advanced disease status; other significant variables for ALL were more advanced disease status at conditioning and cyclosporine-based GVHD prophylaxis.

¶For platelet recovery; other significant variables for AML were second or after complete remission disease status, more advanced disease status, female donor to male recipient donor-recipient sex mismatch, and tacrolimus-based GVHD prophylaxis; other significant variables for ALL were more advanced disease status at conditioning and conditioning other than cyclophosphamide and total body irradiation.

#For acute GVHD, no other significant variables were identified for both AML and ALL.

**For chronic GVHD, other significant variables for AML were more advanced disease status and conditioning other than cyclophosphamide and total body irradiation or busulfan and cyclophosphamide; there were no other significant variables identified for ALL.

††For extensive chronic GVHD, there were no other significant variables identified for AML; another significant variable for ALL was patient male sex.

cumulative incidence of TRM was similar between the 2 groups (CB vs BM = 21% vs 23% at 1 year, 24% vs 25% at 2 years, $P = .83$; Figure 2D).

On multivariate analyses adjusted by other factors, the risk for TRM was higher for CB recipients compared with that for BM recipients among patients with AML (RR = 1.5, 95% CI = 1.0-2.3, $P = .085$; Table 2) with marginal significance. For patients with ALL, the risk for TRM was similar between CB and BM recipients (RR = 1.0, 95% CI = 0.6-1.7, $P = .98$).

Cause of death

Recurrence of the primary disease was the leading cause of death in each group (CB vs BM = 37% vs 33% in patients with AML and 36% vs 41% in patients with ALL). The following causes were infection and organ failure in all groups (Table 4).

Other outcomes of transplantation

Neutrophil and platelet recovery. The unadjusted cumulative incidence of neutrophil recovery or platelet recovery at day 100 was significantly lower in CB recipients for both AML (77% vs 94%) and ALL (80% vs 97%) compared with that among BM recipients ($P < .001$ for both). On multivariate analyses, neutrophil recovery was significantly lower among CB recipients for both AML (RR = 0.4, 95% CI = 0.3-0.5, $P < .001$) and ALL (RR = 0.4, 95% CI = 0.3-0.5, $P < .001$; Table 2).

Table 3. Results of multivariate analysis of overall survival according to disease status at transplantation

	First complete remission			Second or after complete remission			More advanced		
Overall survival	n	RR (95% CI)	P	n	RR (95% CI)	P	n	RR (95% CI)	P
AML									
UBMT	130	1.00		82	1.00		95	1.00	
UCBT	50	2.92 (1.38-6.18)	.005	39	1.24 (0.51-3.04)	.63	81	1.29 (0.84-1.98)	.25
ALL									
UBMT	130	1.00		48	1.00		42	1.00	
UCBT	63	1.60 (0.84-3.05)	.16	21	0.62 (0.22-1.74)	.36	30	0.80 (0.38-1.69)	.57

RR indicates relative risk; CI, confidence interval; UBMT, unrelated bone marrow transplantation; and UCBT, unrelated cord blood transplantation.

The unadjusted cumulative incidence of platelet recovery greater than 50 000/μL at 4 months was significantly lower among CB recipients for both AML (59% vs 85%) and ALL (61% vs 83%) compared with that of BM recipients ($P < .001$ for both). The difference was also significant on multivariate analyses for both AML (RR = 0.3, 95% CI = 0.3-0.4, $P < .001$) and ALL (RR = 0.4, 95% CI = 0.3-0.6, $P < .001$; Table 2).

Acute GVHD. The unadjusted cumulative incidence of grade 2 to 4 acute GVHD was lower among CB recipients compared with that among BM recipients (32% vs 35% in AML, 28% vs 42% in ALL); the difference was significant in patients with ALL ($P = .39$ in AML, $P = .008$ in ALL). The difference was also significant on multivariate analyses in ALL (RR = 0.6, 95% CI = 0.4-1.0, $P = .028$). There was no significant difference in patients with AML (RR = 0.8, 95% CI = 0.6-1.2, $P = .23$; Table 2).

Chronic GVHD. The unadjusted cumulative incidence of chronic GVHD at 1 year after transplantation did not significantly differ between CB recipients and BM recipients in both AML (28% vs 32%, $P = .46$) and ALL (27% vs 30%, $P = .50$). The cumulative incidence of extensive-type chronic GVHD was significantly lower among CB recipients compared with that among BM recipients in both AML (8% vs 20%, $P < .001$) and ALL (10% vs 17%, $P = .034$). On multivariate analyses, the risk of developing chronic GVHD was similar in CB recipients and BM recipients in both AML (RR = 0.9, 95% CI = 0.6-1.4, $P = .79$) and ALL (RR = 1.1, 95% CI = 0.7-1.8, $P = .77$). The risk of developing extensive chronic GVHD was lower in CB recipients compared with BM recipients (RR = 0.4, 95% CI = 0.2-0.7, $P = .004$ in AML, and RR = 0.6, 95% CI, 0.3-1.2, $P = .14$ in ALL) and was significantly different in patients with AML (Table 2).

Discussion

The objective of our study was to investigate the outcomes of HLA-A, -B, low-resolution, and -DRB1 high-resolution 0 to 2 mismatched single-unit unrelated CBT in adult patients with acute leukemia compared with those of HLA-A, -B, -C, and -DRB1 (8 of 8) allele-matched unrelated BMT. Although AML and ALL are different diseases, previous comparisons of unrelated BMT and



Figure 2. Cumulative incidence of relapse or TRM of recipients of CB or BM among patients with AML or ALL. For patients with AML, the cumulative incidence of (A) relapse (CB vs BM = 31% vs 24% at 2 years, $P = .068$) and (C) TRM (CB vs BM = 33% vs 22% at 2 years, $P = .004$) was higher in CB recipients. For patients with ALL, the cumulative incidence of relapse (B) was higher in CB recipients with marginal significance (CB vs BM = 31% vs 24% at 2 years, $P = .085$), but the incidence of TRM (D) was similar in CB and BM recipients (CB vs BM = 24% vs 25% at 2 years, $P = .83$).

Table 4. Causes of death after transplantation of unrelated cord blood or unrelated bone marrow among patients with acute myeloid leukemia or acute lymphoblastic leukemia

	Acute myeloid leukemia		Acute lymphoblastic leukemia	
Cause of death	UCBT	UBMT	UCBT	UBMT
Recurrence of disease	35 (37)	34 (33)	18 (36)	34 (41)
Graft failure/rejection	3 (3)	4 (4)	0 (0)	3 (4)
Graft-versus-host disease	6 (6)	7 (7)	3 (6)	5 (6)
Infection	22 (23)	19 (18)	13 (26)	11 (13)
Idiopathic pneumonia	4 (4)	4 (4)	2 (4)	6 (7)
Organ failure	17 (18)	17 (16)	8 (16)	10 (12)
Secondary cancer	0 (0)	1 (1)	0 (0)	0 (0)
Other causes	5 (5)	5 (5)	2 (4)	4 (5)
Unknown/data missing	2 (2)	13 (13)	4 (8)	10 (12)
Total	94 (100)	104 (100)	50 (100)	83 (100)

Data are presented as n (%).

UCBT indicates unrelated cord blood transplantation; and UBMT, unrelated bone marrow transplantation.

unrelated CBT did not separate these 2 diseases. Our report is the first to show the result of disease-specific analyses with a sufficient number of patients.

For AML patients, the recipients of CB were more likely to have advanced leukemia at the time of transplantation, as reported previously, suggesting that CB was used as an alternative stem cell source in the later phase of unrelated donor searches, especially in adults.[11,12,14] A larger proportion of CB recipients with ALL had the Philadelphia chromosome abnormality, which correlates with highly aggressive ALL and usually requires urgent transplantation, in which CB has an advantage over BM.[21]

Different outcomes of mortality were found between AML and ALL in a controlled comparison using multivariate analyses. Whereas significantly lower OS and LFS rates were observed in CB recipients with AML, rates of overall mortality and treatment failure were similar between CB and BM recipients with ALL. The relapse rate was not different between CBT and BMT in patients with both AML and ALL, which was consistent with previous reports.[11-13] In adult patients with ALL, a previous report showed no difference in the outcome of related compared with unrelated BM or peripheral blood transplantation in 1CR.[22] Favorable disease status at transplantation could be a more important factor affecting outcome rather than the type of stem cell source or donor type in patients with ALL. It is notable that TRM in HLA allele-matched unrelated BM recipients with AML was quite low in our study. This is probably associated with the low incidence of acute and chronic GVHD in the Japanese population, which is thought to be the result of genetic homogeneity.[23-26] Among patients with AML, although the difference was not statistically significant, a higher trend of TRM observed in CB recipients might be associated with higher overall and TRM rates in CB recipients. Reasons for higher TRM could include the graft source and delayed neutrophil recovery. Better supportive care is required after CBT for patients going through a prolonged neutropenic period. Development of better graft engineering or better conditioning regimens would help to decrease the TRM rate in CB recipients. Because relapse was the major cause of death in all groups, any attempt to decrease TRM should preserve the antileukemia effect to improve OS and LFS. Another reason for the higher TRM could be a higher risk patient population, higher risk for both disease status and comorbid conditions, requiring rapid transplantation. Searching for unrelated donors earlier and providing transplantation earlier in the disease course could help to decrease TRM in CB recipients.

Neutrophil and platelet recovery was slower in CB recipients with either AML or ALL, consistent with the results of previous reports.[11,12,27] Multiple studies have reported lower incidence of acute GVHD in CB recipients.[8-10,12,13] In our study, particularly in patients with ALL, the risk of developing grade 2 to 4 acute GVHD in CB recipients was lower compared with BM recipients, which was reported to be lower compared with the incidence reported from Western countries.[23-25] The risk of developing chronic GVHD was similar between CB and BM recipient with either disease, but the risk of developing extensive-type chronic GVHD was lower in CB recipients; the difference was significant in patients with AML. It is notable that there was no increase in the incidence of acute or chronic GVHD in CB recipients among patients with either AML or ALL, despite HLA disparity.

For differences in outcomes between AML and ALL, one possibility is a difference of treatment before conditioning therapy. Most AML patients received a more intense treatment for induction and consolidation therapy compared with that for ALL. There was no adjustment made for previous treatment, and this could be the reason for higher mortality in CBT, which requires a longer time for neutrophil recovery. Another possible cause of the difference in outcomes is the difference in conditioning regimens. Preparative regimens were similar between CB and BM recipients among ALL patients. However, in patients with AML, the proportion of standard regimens, such as cyclophosphamide and TBI or busulfan and cyclophosphamide, was smaller among CB recipients. These differences in the distribution of preparative regimens were also seen in a previous report.[11] Although the final model was adjusted for conditioning regimens, we cannot rule out the possibility of an effect that larger CB recipients received additional or different chemotherapeutic agents compared with BM recipients among patients with AML. Although the difference was small, the median age of CB recipients with AML was 4 years older than CB recipients with ALL (median age, 38 vs 34 years, $P = .021$), which might have affected the higher mortality rate among CB recipients with AML. It is also possible that some unknown biologic aspects have contributed to these differences, and this would require further evaluation in future studies.

Further subgroup analyses indicated that the superiority of HLA allele-matched BM versus CB for OS was mostly found in patients with AML showing 1CR at conditioning. However, because of the limited numbers of patients in these subgroup analyses and the possibility of an unidentified bias in stem cell source selection, our findings should be verified by further analysis in a larger population.

In conclusion, we found different outcomes between patients with AML and ALL, indicating the importance of disease-specific analyses in alternative donor studies. HLA-A, -B low-resolution, and -DRB1 high-resolution 0 to 2 mismatched single-unit CB is a favorable alternative stem cell source for patients without a suitable related or 8 of 8 matched unrelated BM donor. In the absence of a suitable donor, unrelated CBT should be planned promptly to transplant the patient while in a better disease status and better clinical condition. For patients with AML, decreasing mortality, especially in the early phase of transplantation, is required to improve the outcome for CB recipients.

Acknowledgments

The authors thank all the staff members of the collaborating institutes of the Japan Cord Blood Bank Network and Japan Marrow Donor Program for their assistance and cooperation and

Dr Takakazu Kawase for validating human leukocyte antigen data of the Japan Marrow Donor Program.

This work was supported by a Research Grant for Tissue Engineering (H17-014), a Research Grant for Allergic Disease and Immunology (H20-015), and a Research Grant for Cancer (H19-1) from the Japanese Ministry of Health, Labor, and Welfare.

Authorship

Contribution: Y.A. and R.S. designed the study and wrote the paper; Y.A. analyzed results and made the figures; S. Kato and Y.M. designed the research; T.-N.I., H.A., and M. Takanashi reviewed and cleaned the Japan Cord Blood Bank Network data and reviewed the results; S. Taniguchi, S. Takahashi, S. Kai, H.S., Y. Kouzai, M.K., and T.F. submitted and cleaned the data; and S.O., M. Tsuchida, K.K., Y.M., and Y. Kodera reviewed and cleaned the Japan Marrow Donor Program data and reviewed the results.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

A complete list of members from the Japan Marrow Donor Program and the Japan Cord Blood Bank Network can be found in the Supplemental Appendix (available on the *Blood* website; see the Supplemental Materials link at the top of the online article).

Correspondence: Yoshiko Atsuta, Department of Hematopoietic Stem Cell Transplantation Data Management, Nagoya University School of Medicine, 1-1-20 Daiko-Minami, Higashi-ku Nagoya, 461-0047 Japan; e-mail: y-atsuta@med.nagoya-u.ac.jp.

References

1. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767-1777.
2. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.
3. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
4. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood. 1996;88:795-802.
5. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 1996;335:157-166.
6. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors: Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337: 373-381.
7. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565-1577.
8. Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling: Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000;342:1846-1854.
9. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962-2971.
10. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369:1947-1954.
11. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265-2275.
12. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351:2276-2285.
13. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104:3813-3820.
14. Sanz MA. Cord-blood transplantation in patients with leukemia: a real alternative for adults. N Engl J Med. 2004;351:2328-2330.
15. Kodera Y, Morishima Y, Kato S, et al. Analysis of 500 bone marrow transplants from unrelated donors (UR-BMT) facilitated by the Japan Marrow Donor Program: confirmation of UR-BMT as a standard therapy for patients with leukemia and aplastic anemia. Bone Marrow Transplant. 1999; 24:995-1003.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
18. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
19. Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc. 1999;94:456-509.
20. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000;21:552-560.
21. Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002;8:257-260.
22. Kiehl MG, Kraut L, Schwerdtfeger R, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22:2816-2825.
23. Morishima Y, Morishita Y, Tanimoto M, et al. Low incidence of acute graft-versus-host disease by the administration of methotrexate and cyclosporine in Japanese leukemia patients after bone marrow transplantation from human leukocyte antigen compatible siblings; possible role of genetic homogeneity. The Nagoya Bone Marrow Transplantation Group. Blood. 1989;74:2252-2256.
24. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor: Japan Marrow Donor Program. N Engl J Med. 1998;339:1177-1185.
25. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99:4200-4206.
26. Atsuta Y, Suzuki R, Yamamoto K, et al. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Bone Marrow Transplant. 2006;37:289-296.
27. Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109:1322-1330.

Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study

Kenichi Ishizawa,[1,8] Michinori Ogura,[2] Motohiro Hamaguchi,[3] Tomomitsu Hotta,[4] Kazunori Ohnishi,[5] Tsuneo Sasaki,[6] Hisashi Sakamaki,[7] Hisayuki Yokoyama,[1] Hideo Harigae[1] and Yasuo Morishima[2]

[1]Department of Rheumatology and Hematology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574; [2]Department of Hematology and Cell Therapy, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681; [3]Clinical Research Center, National Hospital Organization, Nagoya Medical Center, 4-1-1, San-nomaru, Naka-ku, Nagoya 460-0001; [4]Department of Hematology and Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193; [5]Department of Internal Medicine III, Hamamatsu University School of Medicine, 1-20-1, Handayama, Hamamatsu, Shizuoka 431-3192; [6]Department of Chemotherapy and [7]Department of Hematology, Tokyo Metropolitan Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-j-ku, Tokyo 113-8677, Japan

(Received March 12, 2008/Revised July 23, 2008; September 30, 2008; October 21, 2008/Accepted October 29, 2008/Online publication December 14, 2008)

The purpose of this study was to investigate the safety profile of SR29142 when administered as a single agent both prior to chemotherapy and during treatment, and to compare the efficacy of SR29142 administered at two dose levels in adult Japanese patients with leukemia or lymphoma. During this open-label, multicenter, phase II study, patients received SR29142 for 5 days, administered at either 0.15 or 0.20 mg/kg per day. Chemotherapy was started 4–24 h after the first infusion of SR29142. The primary end-point was overall response rate, defined as the normalization of plasma uric acid to 7.5 mg/dL or less, from 48 h after the first infusion to 24 h after the last infusion of SR29142. SR29142-related adverse events including hypersensitivity (allergic) reactions were assessed. Overall, 50 patients received SR29142 at either 0.15 mg/kg per day (*n* = 25) or 0.20 mg/kg per day (*n* = 25) followed by chemotherapy. The overall response rate was 100.0% (95% confidence interval, 86.3–100.0%) with 0.15 mg/kg and 96.0% (95% confidence interval, 79.6–99.9%) with 0.20 mg/kg. Both dose levels of SR29142 were equally effective at reducing plasma uric acid levels. In six patients, seven drug-related adverse events of grade 1/2 occurred before chemotherapy. SR29142-related, hypersensitivity-associated reactions occurred in three patients, and rash, anorexia, application site pain and pyrexia occurred in one patient each; only five patients (10%) showed anti-SR29142 antibodies by day 29. In conclusion, SR29142 is effective at reducing plasma uric acid levels with a tolerable safety profile as a single agent both prior to chemotherapy and during treatment. (Trial register: ClinicalTrials.gov, NCT00631579.) (*Cancer Sci* 2009; 100: 357–362)

Tumor lysis syndrome (TLS) is a metabolic abnormality caused by the rapid killing of tumor cells during chemotherapy and the subsequent release of intracellular metabolites into the circulation.[1,2] It is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and renal dysfunction, and despite the availability of several preventative measures, can be a life-threatening complication. The formation of uric acid crystals in the renal tubule, tissue precipitation of calcium phosphate, renal tumor infiltration, xanthinuria or use of nephrotoxic drugs may cause renal dysfunction. The prevention of TLS is crucial for the effective treatment of hematological malignancies, especially rapidly proliferating neoplasms including acute lymphoblastic leukemia and high-grade non-Hodgkin's lymphoma.[3] Despite the introduction of new drugs, such as rituximab and fludarabine, TLS remains one of the most serious complications in the treatment of low-grade lymphoma and chronic lymphoblastic leukemia. The overall incidence of TLS in hematological malignancies is reported to be approximately 5%.[4]

General procedures to prevent TLS are hydration, alkalinization of urine with sodium bicarbonate and allopurinol. Allopurinol inhibits the formation of uric acid, thereby controlling the plasma uric acid level through inhibition of xanthine oxidase, which converts hypoxanthine to xanthine, and xanthine to uric acid.[5] However, allopurinol requires 24–48 h to exert its effect on uric acid synthesis and does not affect pre-existing uric acid levels. Furthermore, allopurinol causes increases in serum levels of xanthine and hypoxanthine, which may cause xanthine nephropathy; allopurinol also exhibits drug–drug interactions with several purine-based anticancer drugs.

Rasburicase (SR29142, EC 1.7.3.3, Sanofi-Aventis, Paris, France) is a recombinant urate oxidase enzyme produced in the yeast *Saccharomyces cerevisiae* from the cDNA of *Aspergillus flavus*. SR29142 lowers uric acid levels by converting uric acid to allantoin, which is approximately fivefold more soluble than uric acid and is easily excreted in the urine. Consequently, SR29142 leads (within 4 h) to a rapid decline in uric acid, thereby reducing the risk of TLS. Results of previous clinical trials showed that SR29142 provides early control of hyperuricemia in patients with hyperuricemia prior to dosing and minimizes the risk of hyperuricemia following cytoreductive chemotherapy.[6,7] As SR29142 is a recombinant protein, the development of anti-SR29142 antibodies and hypersensitivity reactions due to this agent are potential major safety issues; however, the relationship between anti-SR29142 antibodies and hypersensitivity reactions remains unclear. To date, there is little information from long-term follow-up studies regarding the development of anti-SR29142 antibodies.

The aim of this phase II study was to investigate the safety and efficacy of SR29142 as a single agent administered before chemotherapy in Japanese patients with leukemia or lymphoma. In particular, the incidence of SR29142-related adverse events (AE), including hypersensitivity reactions prior to initiation of chemotherapy, was studied in order to provide an accurate evaluation of the safety of SR29142 monotherapy excluding the effects of chemotherapy.

Materials and Methods

Study design. This was an open-label, multicenter, phase II study of repeated-dose SR29142 (0.15 or 0.20 mg/kg for 5 days) as uricolytic therapy for hyperuricemia in adult patients with leukemia or lymphoma.

The primary objective was to evaluate the safety and efficacy of SR29142 in Japanese patients with malignant lymphoma or acute leukemia. Secondary objectives included determination of

[8]To whom correspondence should be addressed.
E-mail: kishizaw@mail.tains.tohoku.ac.jp

doi: 10.1111/j.1349-7006.2008.01047.x
© 2008 Japanese Cancer Association